TREXIMET (sumatriptan succinate and naproxen sodium) by Currax Pharmaceuticals is naproxen. Approved for cluster headache, migraine attacks. First approved in 2008.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
TREXIMET is an oral combination tablet containing sumatriptan succinate (a 5-HT1B/1D receptor agonist) and naproxen sodium (an NSAID), approved in 2008 for acute treatment of migraine attacks and cluster headaches. Sumatriptan causes cranial vessel constriction and inhibits neuropeptide release via trigeminal system modulation, while naproxen reduces prostaglandin-mediated inflammation and pain sensitization. This dual-mechanism approach addresses both the vascular and inflammatory components of migraine pathophysiology.
Product is in post-LOE phase with minimal Part D volume ($1M in 2023, 556 claims), indicating a mature/niche market with likely smaller commercial teams focused on retention and specialty positioning.
naproxen. Sumatriptan binds with high affinity to cloned 5-HT 1B / 1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system,…
Worked on TREXIMET at Currax Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
Treximet in the Treatment of Chronic Migraine
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
TREXIMET currently shows zero linked job openings, reflecting its post-LOE status and maturity as a brand. Positions on this product would focus on defending market share against generics and managing decline rather than growth—suitable for professionals seeking stability over rapid career advancement but with limited upside.